FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891243575> ?p ?o ?g. }

• W2891243575 endingPage "3514" @default.
• W2891243575 startingPage "3514" @default.
• W2891243575 abstract "3514 Background: Pembrolizumab is approved for the treatment of adult and pediatric patients (pts) with previously treated MSI-H cancer regardless of tumor type or site. This approval was based in part on data from cohort A of the phase 2 KEYNOTE-164 (NCT02460198) study of pts with MSI-H CRC after ≥2 prior lines of therapy including fluoropyrimidine, oxaliplatin, and irinotecan. In addition, in Cohort B of KEYNOTE-164, we evaluated the activity of pembrolizumab in pts with metastatic MSI-H CRC treated with ≥1 prior line of therapy. Methods: KEYNOTE-164 cohort B enrolled pts with metastatic CRC, MSI-H status confirmed locally by IHC or PCR, and ≥1 prior line of therapy (fluoropyrimidine, oxaliplatin, irinotecan, or anti VEGF/EGFR). Eligible pts received pembrolizumab 200 mg Q3W for 2 years or until progression, unacceptable toxicity, or withdrawal of consent. Tumor response was assessed Q9W per RECIST v1.1 by independent review. The primary endpoint was ORR. Secondary endpoints included DOR, PFS, OS, and safety. Results: Of 63 pts enrolled, median age (range) was 59 years (23-83), and 52% were male. Pts had a median of 2 prior therapies, and 94% had ≥1 prior therapy for advanced disease. As of Sep 12, 2017, median (range) duration of follow-up was 12.6 months (0.1-15.4). ORR was 32% (95% CI, 21-45) with 2 CRs and 18 PRs. Median DOR was not reached (NR); 95% of responses were ongoing with DOR ≥6 mo in 75% of responders. Median PFS was 4.1 month (95% CI, 2.1-NR) with a 12-month PFS rate of 41%. Median OS was NR with a 12-month OS rate of 76%. Forty (64%) pts had any grade treatment-related AEs, most commonly (≥10%) fatigue (18%), hypothyroidism (16%), and hyperthyroidism (11%); 7 (11%) pts had grade 3-4 treatment-related AEs of anemia, thrombocytopenia, diarrhea, pneumatosis intestinalis, arthritis, syncope, pneumonitis, and vasculitis (n = 1 each). There were no treatment-related deaths. Twenty (32%) pts had any grade immune-mediated AEs; 2 (3%) pts had grade 3-4 immune-mediated AEs of colitis and pneumonitis (n = 1 each). Conclusions: Pembrolizumab provided durable antitumor activity with a manageable safety profile in patients with MSI-H CRC that progressed after ≥1 prior line of therapy. Clinical trial information: NCT02460198." @default.
• W2891243575 created "2018-09-27" @default.
• W2891243575 creator A5006614349 @default.
• W2891243575 creator A5010372361 @default.
• W2891243575 creator A5010925062 @default.
• W2891243575 creator A5011776853 @default.
• W2891243575 creator A5015610217 @default.
• W2891243575 creator A5035154674 @default.
• W2891243575 creator A5038208984 @default.
• W2891243575 creator A5039448468 @default.
• W2891243575 creator A5050468802 @default.
• W2891243575 creator A5050481393 @default.
• W2891243575 creator A5050789569 @default.
• W2891243575 creator A5064029009 @default.
• W2891243575 creator A5065275723 @default.
• W2891243575 creator A5066153694 @default.
• W2891243575 creator A5069585958 @default.
• W2891243575 creator A5070275554 @default.
• W2891243575 creator A5079825829 @default.
• W2891243575 creator A5090645179 @default.
• W2891243575 date "2018-05-20" @default.
• W2891243575 modified "2023-10-16" @default.
• W2891243575 title "KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer." @default.
• W2891243575 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.3514" @default.
• W2891243575 hasPublicationYear "2018" @default.
• W2891243575 type Work @default.
• W2891243575 sameAs 2891243575 @default.
• W2891243575 citedByCount "54" @default.
• W2891243575 countsByYear W28912435752018 @default.
• W2891243575 countsByYear W28912435752019 @default.
• W2891243575 countsByYear W28912435752020 @default.
• W2891243575 countsByYear W28912435752021 @default.
• W2891243575 countsByYear W28912435752022 @default.
• W2891243575 countsByYear W28912435752023 @default.
• W2891243575 crossrefType "journal-article" @default.
• W2891243575 hasAuthorship W2891243575A5006614349 @default.
• W2891243575 hasAuthorship W2891243575A5010372361 @default.
• W2891243575 hasAuthorship W2891243575A5010925062 @default.
• W2891243575 hasAuthorship W2891243575A5011776853 @default.
• W2891243575 hasAuthorship W2891243575A5015610217 @default.
• W2891243575 hasAuthorship W2891243575A5035154674 @default.
• W2891243575 hasAuthorship W2891243575A5038208984 @default.
• W2891243575 hasAuthorship W2891243575A5039448468 @default.
• W2891243575 hasAuthorship W2891243575A5050468802 @default.
• W2891243575 hasAuthorship W2891243575A5050481393 @default.
• W2891243575 hasAuthorship W2891243575A5050789569 @default.
• W2891243575 hasAuthorship W2891243575A5064029009 @default.
• W2891243575 hasAuthorship W2891243575A5065275723 @default.
• W2891243575 hasAuthorship W2891243575A5066153694 @default.
• W2891243575 hasAuthorship W2891243575A5069585958 @default.
• W2891243575 hasAuthorship W2891243575A5070275554 @default.
• W2891243575 hasAuthorship W2891243575A5079825829 @default.
• W2891243575 hasAuthorship W2891243575A5090645179 @default.
• W2891243575 hasConcept C104317684 @default.
• W2891243575 hasConcept C121608353 @default.
• W2891243575 hasConcept C126322002 @default.
• W2891243575 hasConcept C141071460 @default.
• W2891243575 hasConcept C143998085 @default.
• W2891243575 hasConcept C180754005 @default.
• W2891243575 hasConcept C185592680 @default.
• W2891243575 hasConcept C203092338 @default.
• W2891243575 hasConcept C2777701055 @default.
• W2891243575 hasConcept C2779767149 @default.
• W2891243575 hasConcept C2780057760 @default.
• W2891243575 hasConcept C2780259306 @default.
• W2891243575 hasConcept C2780962732 @default.
• W2891243575 hasConcept C526805850 @default.
• W2891243575 hasConcept C535046627 @default.
• W2891243575 hasConcept C55493867 @default.
• W2891243575 hasConcept C61320498 @default.
• W2891243575 hasConcept C71924100 @default.
• W2891243575 hasConcept C72563966 @default.
• W2891243575 hasConcept C90924648 @default.
• W2891243575 hasConceptScore W2891243575C104317684 @default.
• W2891243575 hasConceptScore W2891243575C121608353 @default.
• W2891243575 hasConceptScore W2891243575C126322002 @default.
• W2891243575 hasConceptScore W2891243575C141071460 @default.
• W2891243575 hasConceptScore W2891243575C143998085 @default.
• W2891243575 hasConceptScore W2891243575C180754005 @default.
• W2891243575 hasConceptScore W2891243575C185592680 @default.
• W2891243575 hasConceptScore W2891243575C203092338 @default.
• W2891243575 hasConceptScore W2891243575C2777701055 @default.
• W2891243575 hasConceptScore W2891243575C2779767149 @default.
• W2891243575 hasConceptScore W2891243575C2780057760 @default.
• W2891243575 hasConceptScore W2891243575C2780259306 @default.
• W2891243575 hasConceptScore W2891243575C2780962732 @default.
• W2891243575 hasConceptScore W2891243575C526805850 @default.
• W2891243575 hasConceptScore W2891243575C535046627 @default.
• W2891243575 hasConceptScore W2891243575C55493867 @default.
• W2891243575 hasConceptScore W2891243575C61320498 @default.
• W2891243575 hasConceptScore W2891243575C71924100 @default.
• W2891243575 hasConceptScore W2891243575C72563966 @default.
• W2891243575 hasConceptScore W2891243575C90924648 @default.
• W2891243575 hasIssue "15_suppl" @default.
• W2891243575 hasLocation W28912435751 @default.
• W2891243575 hasOpenAccess W2891243575 @default.
• W2891243575 hasPrimaryLocation W28912435751 @default.
• W2891243575 hasRelatedWork W2051540233 @default.

• next